topiramate/phentermine / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 45 Diseases   9 Trials   9 Trials   519 News 


1234567»
  • ||||||||||  Xenical (orlistat) / Roche, GSK, Imcivree (setmelanotide) / Rhythm Pharma
    Review, Journal:  Obesity Medications and Their Impact on Cardiovascular Health: A Narrative Review. (Pubmed Central) -  Nov 19, 2024   
    Obesity medications differ in their effects on cardiovascular health, with some offering more consistent benefits. More studies are needed to fully understand their long-term risks and benefits, but combining medication with lifestyle changes remains key to improving both weight and heart health.
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen, Xenical (orlistat) / Roche, GSK
    Journal:  Long-Term Assessment of Weight Loss Medications in a Veteran Population. (Pubmed Central) -  Oct 16, 2024   
    However, there were no statistically significant differences among the medications. Patients did not receive uniformly consistent follow-up care, suggesting the need for more standardized processes that could lead to better weight loss outcomes.
  • ||||||||||  Visken (pindolol) / Novartis, NN1213 / Novo Nordisk
    Enrollment change:  Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate (clinicaltrials.gov) -  Oct 16, 2024   
    P2,  N=47, Completed, 
    Patients did not receive uniformly consistent follow-up care, suggesting the need for more standardized processes that could lead to better weight loss outcomes. N=80 --> 47
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen, Xenical (orlistat) / Roche, GSK
    Review, Journal:  Weight Loss Pharmacotherapy: Current and Future Therapies. (Pubmed Central) -  Sep 15, 2024   
    Future research is needed to investigate how to safely utilize these agents. There are currently 5 Food and Drug Administration-approved medications for the treatment of obesity: orlistat, phentermine/topiramate, naltrexone/bupropion, liraglutide 3.0
  • ||||||||||  Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen, Mounjaro (tirzepatide) / Eli Lilly
    Use of weight-loss medications in adults with cystic fibrosis and obesity: a retrospective study () -  Sep 4, 2024 - Abstract #NACFC2024NACFC_1218;    
    Gastrointestinal side effects were mild and consistent with what has been reported in the general population. Future prospective studies are needed to address long-term efficacy and safety of anti-obesity medications in PwCF.
  • ||||||||||  Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen, Xenical (orlistat) / Roche, GSK
    Weighting on Methane: Weight Loss Medications Associated With Increased Incidence of SIBO (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_2856;    
    Of these, 990 were IMO positive, 249 were H-SIBO positive and 242 were positive by both criteria. GLP-1 usage was associated with IMO (OR 2.18, 95% confidence interval 1.01-4.72) and H-SIBO (OR 2.01, 95% confidence interval 1.04-3.88) positivity.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Contrave (naltrexone/bupropion) / Currax, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
    Analysis of Provider Preferences for AI-Generated Responses to Anti-Obesity Treatments (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_1952;    
    FDA provided responses were significantly shorter (99 words) than those of either Gemini (186 words) or GPT-4 (252 words), p< 0.001. 85% of all responses were deemed accurate, and there was no significant difference between LLM and FDA responses.
  • ||||||||||  Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen, Xenical (orlistat) / Roche, GSK, Imcivree (setmelanotide) / Rhythm Pharma
    Journal:  Obesity management in the pediatric patient. (Pubmed Central) -  Aug 16, 2024   
    Pharmacotherapy may also be considered, yet no medication is recommended over another, giving flexibility for shared decision-making with the patient and family regarding comorbidities and potential drug interactions. Adolescents with severe obesity who meet specified criteria may also be referred for surgical evaluation.
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen, Xenical (orlistat) / Roche, GSK
    Review, Journal:  Anti-obesity Drugs for the Treatment of Binge Eating Disorder: Opportunities and Challenges. (Pubmed Central) -  Aug 16, 2024   
    Findings from ongoing clinical trials are likely to provide further insight into the possible role of anti-obesity drugs for treating BED. Since these agents can hold the potential to be misused potentiating dietary restriction and pathological weight loss, it is crucial to promote responsible prescribing practices.
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
    Review, Journal:  Obesity in Adolescents: A Review. (Pubmed Central) -  Aug 5, 2024   
    Intensive lifestyle modification therapy reduces BMI by approximately 3% while pharmacotherapy added to lifestyle modification therapy can attain BMI reductions ranging from 5% to 17%. Surgery is the most effective intervention for adolescents with severe obesity and has been shown to achieve BMI reduction of approximately 30%.
  • ||||||||||  Clinical, Review, Journal:  Medications for Obesity: A Review. (Pubmed Central) -  Jul 22, 2024   
    Obesity is associated with increased morbidity. Antiobesity medications are effective adjunctive therapy to lifestyle changes for improved weight loss and health outcomes.
  • ||||||||||  Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
    Enrollment open, Trial initiation date:  Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity (clinicaltrials.gov) -  Jul 22, 2024   
    P2,  N=24, Recruiting, 
    Antiobesity medications are effective adjunctive therapy to lifestyle changes for improved weight loss and health outcomes. Not yet recruiting --> Recruiting | Initiation date: May 2024 --> Aug 2024
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen, Xenical (orlistat) / Roche, GSK
    Trial termination:  EMPOWER-T2D: EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial (clinicaltrials.gov) -  Jul 22, 2024   
    P4,  N=74, Terminated, 
    The study was closed due to futility. All Patients are off study and this study will not resume.
  • ||||||||||  Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen, Xenical (orlistat) / Roche, GSK
    Review, Journal:  Effective and appropriate use of weight loss medication in pediatric obesity: a narrative review. (Pubmed Central) -  Jul 2, 2024   
    Sufficient lifestyle modification therapy should be administered before considering pharmacotherapy and continued after the initiation of AOM. To ensure healthy development, monitoring growth and puberty development during anti-obesity treatments is essential.
  • ||||||||||  Visken (pindolol) / Novartis, NN1213 / Novo Nordisk
    Trial completion, Enrollment change, Trial completion date:  Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate (clinicaltrials.gov) -  Jun 13, 2024   
    P2,  N=80, Completed, 
    Evidence is lacking about how weight management interventions affect BMI beyond 1 year and after medication discontinuation and about longer-term effects on other outcomes. Recruiting --> Completed | N=134 --> 80 | Trial completion date: Feb 2025 --> Jun 2024
  • ||||||||||  Review, Journal:  Sex, race, and BMI in clinical trials of medications for obesity over the past three decades: a systematic review. (Pubmed Central) -  May 23, 2024   
    Our systematic review suggests that future trials need to recruit traditionally under-represented populations to allow for accurate measures of efficacy of medications for obesity, enabling more informed decisions by clinicians. It is also hoped that these data will help to refine trial recruitment strategies to ensure that future studies are relevant to the population affected by obesity.
  • ||||||||||  CONCRETE (Poster Hall (West A4-B2); 1684) -  May 20, 2024 - Abstract #ADA2024ADA_2633;    
    Additional research is needed to assess trends in utilization and adherence to minimize the risk of worsening socioeconomic disparities in pediatric obesity. In this study, Wegovy
  • ||||||||||  Practice Patterns of Medical Management of Pediatric Obesity and Type 1 Diabetes (T1D) (Poster Hall (West A4-B2); 1177) -  May 20, 2024 - Abstract #ADA2024ADA_2511;    
    Despite recent FDA approval of new weight loss medications for children and adolescents, few were prescribed GLP1-RA. Further research is needed to understand patient/family and provider perspectives on these medications and their potential benefits for young people with T1D.
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen, Xenical (orlistat) / Roche, GSK
    Journal, Surgery, Bariatric surgery:  Utilization of Anti-obesity Medications After Bariatric Surgery: Analysis of a Large National Database. (Pubmed Central) -  Apr 22, 2024   
    Despite a relatively high incidence of weight regain, AOMs are underutilized following bariatric surgery. It is imperative that barriers to their use be addressed and that AOMs be considered earlier and more frequently in patients with insufficient weight loss or weight regain after bariatric surgery.
  • ||||||||||  Journal, Real-world evidence, Real-world:  Comparison of the Efficacy of Anti-Obesity Medications in Real-World Practice. (Pubmed Central) -  Mar 29, 2024   
    All the AOMs were effective at inducing and maintaining weight loss, in the absence of significant changes in muscle mass, over a 6 month period, and the short-term use of phentermine and the long-term use of phentermine/topiramate or liraglutide would be practical choices for the treatment of obesity. However, further, large-scale studies are necessary to confirm these findings.
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen, Mounjaro (tirzepatide) / Eli Lilly
    EVALUATION OF THE COST EFFECTIVENESS OF AVAILABLE MEDICATION THERAPIES FOR WEIGHT LOSS: A MICROSIMULATION ANALYSIS (Hall A, Poster Hall - Walter E. Washington Convention Center) -  Mar 14, 2024 - Abstract #DDW2024DDW_1362;    
    Tirzepatide has the potential to be cost-effective due to significantly more effective weight loss but requires a substantial cost reduction. When prioritizing AOMs, we must also account for cost-effectiveness to appropriately direct resources in the development of health policy.
  • ||||||||||  Visken (pindolol) / Novartis, NN1213 / Novo Nordisk
    Trial primary completion date:  Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate (clinicaltrials.gov) -  Feb 19, 2024   
    P2,  N=134, Recruiting, 
    No abstract available Trial primary completion date: Feb 2024 --> Feb 2025
  • ||||||||||  Saxenda (liraglutide 3 mg) / Novo Nordisk
    Trial completion date, Trial primary completion date, Inflammatory cell:  Anti-obesity Pharmacotherapy and Inflammation (clinicaltrials.gov) -  Feb 15, 2024   
    P=N/A,  N=24, Recruiting, 
    Trial primary completion date: Feb 2024 --> Feb 2025 Trial completion date: Apr 2024 --> Dec 2024 | Trial primary completion date: Feb 2024 --> Sep 2024
  • ||||||||||  Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
    Trial completion:  Phase IV Study of Qsymia in Obese Patients (clinicaltrials.gov) -  Jan 31, 2024   
    P4,  N=232, Completed, 
    Recruiting --> Active, not recruiting Recruiting --> Completed
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen, Xenical (orlistat) / Roche, GSK
    CONTEMPORARY ANTI-OBESITY PHARMACOTHERAPY PRESCRIBING PATTERNS IN A LARGE U.S. TERTIARY HEALTHCARE SYSTEM, 2018-2022 (Hall B4-5) -  Jan 26, 2024 - Abstract #ACC2024ACC_5569;    
    In this large U.S. tertiary care system, AOM prescription increased nearly 10-fold between 2018-2022, but remains substantially limited. Given expanding outcomes data, further efforts are needed to engage cardiovascular medicine clinicians in anti-obesity care.
  • ||||||||||  Review, Journal:  Pharmacologic management of obesity: Updates on approved medications, indications and risks. (Pubmed Central) -  Jan 23, 2024   
    AOMs have established efficacy and effectiveness for weight loss even beyond 52?weeks. Further pharmacological options, such as dual and triple incretins, are probable forthcoming additions to clinical practice for combating obesity and its metabolic consequences such as metabolic dysfunction-associated steatotic liver disease.
  • ||||||||||  Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
    Biomarker, Enrollment open:  Risk of Metabolic Adaptation After Weight Loss (clinicaltrials.gov) -  Jan 7, 2024   
    P=N/A,  N=60, Recruiting, 
    Further pharmacological options, such as dual and triple incretins, are probable forthcoming additions to clinical practice for combating obesity and its metabolic consequences such as metabolic dysfunction-associated steatotic liver disease. Active, not recruiting --> Recruiting
  • ||||||||||  Contrave (naltrexone/bupropion) / Currax, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen, Saxenda (liraglutide 3 mg) / Novo Nordisk
    Journal, Surgery, Bariatric surgery:  Factors contributing to whether or not people with obesity undergo bariatric surgery. (Pubmed Central) -  Dec 18, 2023   
    A variety of characteristics were associated with decisions to undergo bariatric surgery. These findings may help to determine ways to support individuals who are considering bariatric surgery.
  • ||||||||||  Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen, Xenical (orlistat) / Roche, GSK
    Review, HEOR:  Pharmacoeconomic evaluation of anti-obesity drugs for chronic weight management: a systematic review of literature. (Pubmed Central) -  Dec 3, 2023   
    Most of the economic assessments were still about Orlistat...A few studies were on the combined therapies (i.e. PHEN/TPM ER and NB ER) compared to different comparators, which could hardly lead to a generalized summary of the cost-effectiveness...Future modelling evaluations would benefit from a better understanding of the long-term weight loss effects of the current therapeutic options and the weight rebound process after the discontinuation of treatment. https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022302648, identifier CRD42022302648.